Herantis Pharma granted almost €3 million government loan for Parkinson’s study

News

Author: Parkinson's Life editorsPublished: 15 August 2015

Prep: Cook: Serves:

Tekes, the Finnish Funding Agency for Innovation, has granted a €2,903,000 loan to Herantis Pharma Plc to support its clinical study of CDNF for the treatment of Parkinson’s disease. The loan was granted conditionally, subject to obtaining regulatory approval for the clinical study.

Pekka Simula, CEO of Herantis Pharma, added: “We are very excited about our opportunity to translate the results of years of leading academic research to clinical stage, hopefully for the benefit of as many patients as possible.”

Herantis aims to start its clinical development programme with regulatory submissions in Finland and Sweden by the end of 2015. Patient treatments are expected to begin in the first half of 2016. The company expects to recruit 18 patients with Parkinson’s disease in this first-in-human study of CDNF.

Last Month

Next Month

Go Back

Share this story

Comments

Global update

No Escape Room: a Parkinson’s campaign like no other

The escape room simulates common Parkinson’s symptoms

Advances

Hitting the sweet spot: how the new directional DBS system improves symptom control in Parkinson’s disease

New tech can find the brain’s ‘sweet spot’ for improved effectiveness

The women blazing the trail in Parkinson’s tech and innovation

Have you heard about these Parkinson’s technology inventions?

Wearable device for Parkinson’s disease raises $10m in funding

UK-based tech company Charco Neurotech has secured $10 million in seed investment funding to support the launch of a non-invasive wearable device designed for people with Parkinson’s disease. CUE1 is a circular device worn on the sternum, which is designed to help alleviate Parkinson’s symptoms through specialised vibrations that are personalised for each patient. The investment round, which was co-led by venture capital company Amadeus Capital Partners and growth fund managers Parkwalk Advisors, is the largest European seed financing in 2021 for a heath technology device – and the sixth largest globally. Lucy Jung, co-founder and CEO of Charco Neurotech, said: “This funding will enable us to proceed with our first, limited launch, while we work to ensure our manufacturing line is robust and produces consistent high quality devices.” Charco also recently announced a new partnership with the European Parkinson’s Disease Association (EPDA), to help increase the availability of Charco’s…

Does Parkinson’s disease start in the nose?

An international team led by the University of Ottawa in Canada will study whether the scent-processing nerves inside the nose may play a part in the development of Parkinson’s disease. The researchers will explore potential connections between inflammation, environmental exposures in the nasal cavity, odour processing centres in the brain and Parkinson’s-related genes. The scientists hope that if the study indicates that Parkinson’s starts in the nose, early signs of the condition could potentially be detected sooner. This research, which will use human and animal models, has been made possible by a US $9m grant from the Aligning Science Across Parkinson’s (ASAP) initiative, which aims to improve understanding of the causes of the condition. “This grant will allow us to explore an understudied but important aspect of Parkinson’s, which could lead to new approaches for early treatment and prevention,” said Professor Michael Schlossmacher, team leader of the study.

Study finds gene therapy may restore effects of Parkinson’s drug

Levodopa is a drug commonly used to treat Parkinson’s as it helps to increase dopamine levels in the brain and improve problems with movement. In later stages of the condition, however, this treatment can become less effective. Now, findings from a US preclinical study have suggested that a new gene therapy may help to restore the effects of levodopa in people with the condition. The researchers used mice models of Parkinson’s to test the effects of the gene therapy, targeting a small region in the brain where dopamine-releasing neurons are present. They found that the therapy increased the neurons’ ability to convert levodopa to dopamine – and discovered that damage to the mitochondria in dopamine-releasing neurons may be enough to trigger Parkinson’s onset. The scientists hope their findings will encourage the development of therapies to preserve the function of these neurons, and support patients in the later stages of Parkinson’s.

All fields required

First name*
Last name*
Email address*
Enter Email Confirm Email
Country of residence*
About me*
- I have Parkinson's disease
- I am a partner / carer / family / friend of someone who has Parkinson's
- I am a healthcare professional with an interest in Parkinson's
- I work for a Parkinson's disease organisation
- Other
CAPTCHA
*
- By proceeding you agree to our
Name
This field is for validation purposes and should be left unchanged.

Herantis Pharma granted almost €3 million government loan for Parkinson’s study

News

Author: Parkinson's Life editorsPublished: 15 August 2015

Prep: Cook: Serves:

Last Month

Next Month

Share this story

Comments

Global update

No Escape Room: a Parkinson’s campaign like no other

sponsored article

Advances

Hitting the sweet spot: how the new directional DBS system improves symptom control in Parkinson’s disease

Women and Parkinson's

The women blazing the trail in Parkinson’s tech and innovation

Wearable device for Parkinson’s disease raises $10m in funding

Does Parkinson’s disease start in the nose?

Study finds gene therapy may restore effects of Parkinson’s drug

{title}

Subscribe

Herantis Pharma granted almost €3 million government loan for Parkinson’s study

News

Author: Parkinson's Life editorsPublished: 15 August 2015

Last Month

Next Month

Share this story

Comments

Related articles

Global update

No Escape Room: a Parkinson’s campaign like no other

sponsored article

Advances

Hitting the sweet spot: how the new directional DBS system improves symptom control in Parkinson’s disease

Women and Parkinson's

The women blazing the trail in Parkinson’s tech and innovation

Wearable device for Parkinson’s disease raises $10m in funding

Does Parkinson’s disease start in the nose?

Study finds gene therapy may restore effects of Parkinson’s drug

{title}

Subscribe

Sign in